Walethmade%2525252525252525252525252525252525252525252525252525252525252525252520bromide

# Walethmade bromide (Glycopyrrolate) ## Overview Walethmade bromide is the generic reference for **glycopyrrolate**, a synthetic quaternary ammonium anticholinergic agent. It does not cross the blood-brain barrier effectively, resulting in fewer central nervous system side effects compared to atropine. ## Primary Indications * **Preoperative:** Reduction of salivary, tracheobronchial, and pharyngeal secretions. * **Intraoperative:** Protection against cholinergic effects (e.g., bradycardia) associated with reversal of neuromuscular blockade. * **Peptic Ulcer:** Adjunctive treatment (historical/limited use). * **Drooling/Sialorrhea:** Management of severe chronic sialorrhea in children with neurologic conditions. ## Adult Dosing * **Preanesthetic/Antisialagogue:** 0.1 mg to 0.2 mg IM/IV administered 30–60 minutes prior to anesthetic induction. * **Intraoperative Bradycardia (Reversal):** 0.1 mg IV, repeated every 2–3 minutes as needed. * **Peptic Ulcer (Oral):** 1 mg three times daily or 2 mg twice daily; maintenance dose is typically 1 mg twice daily. Maximum 8 mg/day. ## Pediatric Dosing * **Antisialagogue:** 0.004–0.01 mg/kg IM/IV (max 0.1–0.2 mg/dose). * **Chronic Sialorrhea (Oral):** Starting dose 0.02 mg/kg three times daily. Titrate every 5–7 days based on efficacy and tolerance; usual maintenance is 0.04–0.1 mg/kg per dose. Consult institutional protocols for specific weight-based escalation. ## Dose Adjustments * **Renal Impairment:** Glycopyrrolate is excreted primarily by the kidneys. Use caution in patients with renal failure. Dose reduction or increased dosing intervals may be required. * **Hepatic Impairment:** No formal adjustments, but monitor for toxic accumulation. ## Contraindications * Known hypersensitivity. * Glaucoma (narrow-angle). * Obstructive uropathy (e.g., prostatic hypertrophy). * Obstructive GI disease (e.g., pyloric stenosis, paralytic ileus). * Tachycardia/Unstable cardiovascular status in acute hemorrhage. * Myasthenia gravis (unless using to treat muscarinic side effects of cholinergic therapy). ## Adverse Effects * **Common:** Dry mouth (xerostomia), constipation, urinary retention, blurred vision, tachycardia, and decreased sweating (anhidrosis). * **Serious:** Heat prostration (at high ambient temperatures), arrhythmias, paradoxical bradycardia (with low doses or IM injection). ## Key Drug Interactions * **Potentiation:** Increased anticholinergic effects when combined with antihistamines, tricyclic antidepressants, or phenothiazines. * **Decreased Effect:** May decrease absorption of concurrently administered oral medications due to delayed gastric emptying. ## Monitoring * Heart rate (ECG if intraoperative). * Blood pressure. * Signs of urinary retention or constipation. * Ocular assessment (for vision changes). * In pediatric sialorrhea: monitor for behavioral changes or severe constipation. ## Clinical Pearls * Glycopyrrolate is more potent and longer-acting than atropine for inhibition of secretions. * Does not produce sedation or amnesia due to poor CNS penetration. * When used for sialorrhea, instruct caregivers to monitor for "signs of overdose" such as flushed skin, agitation, or severe dry mouth. * Dosing varies significantly depending on local institutional guidelines, particularly for chronic pediatric use; consult specific hospital policies or product-specific FDA-approved labeling (e.g., Cuvposa). *** **Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by institution and patient-specific factors. Always verify current prescribing information, dose-limiting toxicities, and safety guidelines through hospital-approved drug databases (e.g., Lexicomp, Micromedex) or the official manufacturer’s product insert before prescribing or administering medication.